Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 286

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 286
---
0.1
million, realized gains of less than $0.1
million and less than $0.1 million,
and unrealized gain of $0
and $0.1
million, respectively.

Fair
Value of Financial Instruments

The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:

    ●
    Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

    ●
    Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.

    ●
    Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.

Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.

    F-9

The
carrying amounts of the Company’s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.

Set
out below are the Company’s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2024 and 2023:

 Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

    December